Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the month of October 2023. The report, dated October 9, 2023, serves primarily to distribute a press release (Exhibit 99.1) to U.S. investors. The company is headquartered in Marseille, France.
Key Financial Metrics
The filing text does not provide specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are included in this document. The filing acts as a conduit for a press release rather than a financial statement.
Material Changes
The filing text does not contain comparative financial data or details regarding material changes versus prior periods. Any material changes would be detailed in the referenced press release, which is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, or details on contingencies and unusual items. These elements are likely contained within the attached press release (Exhibit 99.1) but are not present in the Form 6-K cover sheet provided.
Investor Verification Checklist
- Verify the content of the press release dated October 9, 2023 (Exhibit 99.1), as the Form 6-K itself contains no operational or financial details.
- Confirm the nature of the announcement (e.g., clinical trial results, partnership, or corporate governance) referenced in the exhibit.
- Review the company's most recent Form 20-F for the latest audited financial statements and comprehensive risk factors.